Literature DB >> 23461618

Noninvasive fibrosis indices predict intrahepatic distant recurrence of hepatitis B-related hepatocellular carcinoma following radiofrequency ablation.

Ji Yeon Seo1, Won Kim, Jee Hye Kwon, Eun Hyo Jin, Su Jong Yu, Hwi Young Kim, Yong Jin Jung, Donghee Kim, Yoon Jun Kim, Jung-Hwan Yoon, Hyo-Suk Lee.   

Abstract

BACKGROUNDS & AIMS: Intrahepatic recurrence of hepatocellular carcinoma (HCC) after radiofrequency ablation (RFA) occurs as a result of direct dissemination or de novo oncogenesis. Hepatocellular carcinogenesis is related to the progression of cirrhosis, and noninvasive fibrosis scoring systems reflect the severity of hepatic fibrosis. Hence, the aim of this study was to elucidate the correlation between noninvasive fibrosis indices and intrahepatic distant recurrence (IDR) of HCC after RFA.
METHODS: Patients with hepatitis B virus (HBV)-related, solitary HCC undergoing RFA were prospectively enrolled. Noninvasive serum fibrosis indices were calculated at the time of RFA. IDR was defined as recurrent HCC beyond >2 cm from the ablation margin of RFA. Predictors of IDR and overall survival were analysed by a Cox regression model.
RESULTS: Two hundred forty-six patients received RFA as initial treatment, and the median follow-up duration was 19.7 months (IQR, 11.9-29.8). Among these cases, 133 (45.9%) showed IDR after RFA. In multivariable analysis, serum alpha-fetoprotein (AFP) (HR, 1.000; 95% CI, 1.000-1.001; P = 0.001) and age-platelet index (API) (1.19; 1.01-1.39; P = 0.033) were independent predictors of IDR. In particular, patients with API ≤7 showed a significantly higher recurrence-free survival rate than patients with API >7 (P = 0.004). With regard to overall survival, male sex (4.69; 1.52-14.52; P = 0.007), serum bilirubin (2.78; 1.31-5.90; P = 0.008) and AFP (1.000; 1.000-1.001; P = 0.006) were significantly correlated with shortened survival.
CONCLUSION: High levels of AFP and API predict IDR of HBV-related HCC after RFA. Therefore, noninvasive fibrosis indices could play an important role in predicting IDR of HCC following percutaneous ablation.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23461618     DOI: 10.1111/liv.12132

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  8 in total

Review 1.  Predicting recurrence following radiofrequency percutaneous ablation for hepatocellular carcinoma.

Authors:  Nathalie Ganne-Carrié; Jean-Charles Nault; Marianne Ziol; Gisèle N'Kontchou; Pierre Nahon; Véronique Grando; Valérie Bourcier; Sandrine Barge; Michel Beaugrand; Jean-Claude Trinchet; Olivier Seror
Journal:  Hepat Oncol       Date:  2014-12-11

2.  Prognostic factors of hepatocellular carcinoma survival after radiofrequency ablation: A US population-based study.

Authors:  Mohamed Abd El-Fattah; Mohamed Aboelmagd; Mohammed Elhamouly
Journal:  United European Gastroenterol J       Date:  2016-07-09       Impact factor: 4.623

3.  Significance of platelet count and platelet-based models for hepatocellular carcinoma recurrence.

Authors:  Qing Pang; Jing-Yao Zhang; Xin-Sen Xu; Si-Dong Song; Kai Qu; Wei Chen; Yan-Yan Zhou; Run-Chen Miao; Su-Shun Liu; Ya-Feng Dong; Chang Liu
Journal:  World J Gastroenterol       Date:  2015-05-14       Impact factor: 5.742

4.  Is there an optimal staging system or liver reserve model that can predict outcome in hepatocellular carcinoma?

Authors:  Veeravich Jaruvongvanich; Tomoki Sempokuya; Linda Wong
Journal:  J Gastrointest Oncol       Date:  2018-08

5.  Use of transient elastography to predict de novo recurrence after radiofrequency ablation for hepatocellular carcinoma.

Authors:  Sang Hoon Lee; Seung Up Kim; Jeong Won Jang; Si Hyun Bae; Sanghun Lee; Beom Kyung Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han
Journal:  Onco Targets Ther       Date:  2015-02-02       Impact factor: 4.147

6.  The Dynamic Changes of AFP From Baseline to Recurrence as an Excellent Prognostic Factor of Hepatocellular Carcinoma After Locoregional Therapy: A 5-Year Prospective Cohort Study.

Authors:  Qi Wang; Biyu Liu; Wenying Qiao; Jianjun Li; Chunwang Yuan; Jiang Long; Caixia Hu; Chaoran Zang; Jiasheng Zheng; Yonghong Zhang
Journal:  Front Oncol       Date:  2021-12-16       Impact factor: 6.244

Review 7.  The Prognostic Value of Platelet Count in Patients With Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Qing Pang; Kai Qu; Jing-Yao Zhang; Si-Dong Song; Su-Shun Liu; Ming-Hui Tai; Hao-Chen Liu; Chang Liu
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

8.  A Novel Scoring System for Patients with Recurrence of Hepatocellular Carcinoma After Undergoing Minimal Invasive Therapies.

Authors:  Yan Zhao; Yonghong Zhang; Qi Wang; Liang Ma; Jianjun Li; Chunwang Yuan; Jianping Sun; Kang Li; Ling Qin; Chaoran Zang; Yanan Zhao
Journal:  Cancer Manag Res       Date:  2019-12-20       Impact factor: 3.989

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.